ANI Pharmaceuticals, Inc.ANIPNASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank14
3Y CAGR-39.7%
5Y CAGR-16.0%
Year-over-Year Change
Enterprise value to EBITDA ratio
3Y CAGR
-39.7%/yr
vs +38.7%/yr prior
5Y CAGR
-16.0%/yr
Recent deceleration
Acceleration
-78.4pp
Decelerating
Percentile
P14
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 7.83 | -68.1% |
| 2024 | 24.51 | +147.2% |
| 2023 | 9.92 | -72.2% |
| 2022 | 35.64 | -85.5% |
| 2021 | 246.31 | +1219.0% |
| 2020 | 18.67 | +32.9% |
| 2019 | 14.06 | +45.9% |
| 2018 | 9.63 | -39.8% |
| 2017 | 16.00 | +14.5% |
| 2016 | 13.98 | - |